MAGICAL BTK: Randomized Controlled Trial of MAGIcTouch - Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

Status: Recruiting
Location: See all (23) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a Pivotal, Prospective, randomised, two arm, placebo controlled, single-blind, multicentre trial that will be conducted at approximately 70 sites; approx. 40 sites with at least 50% of subjects will be recruited from USA and approx. 30 sites OUS - Singapore, Australia and Japan. Each site will be capped at 30 maximum subjects recruited. The main goal of this clinical trial is to determine the effectiveness and safety of the sirolimus drug coated balloon (DCB) versus standard percutaneous transluminal angioplasty (PTA) for the treatment of below the knee arterial disease. Eligible subjects will be randomised in a 1:1 allocation ratio and stratified by recruiting countries. Each subject will be randomized to receive either: 1. MagicTouch PTA sirolimus coated balloon catheter (DCB) in addition to standard balloon angioplasty or 2. Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 99
Healthy Volunteers: f
View:

• Age \> 21 years or minimum age (is allowed the inclusion of subjects \> 21 years OR adulthood minimum age (depending on the US state regulations)

• Rutherford class 4 with documented WIFI score, not exceeding more than 30% of target patient population.

• Rutherford class 5 to 6 in the target limb with documented WIFI score.

• Intraoperative Inclusion Criteria:

• Single or sequential de novo or re-stenotic lesions (stenosis of \> 50% or occlusions) from 2 to 20cm in the proximal 200mm of below the knee arteries. Lesion is considered as one lesion if there is maximum of 30 mm gap between lesions at discretion of investigator. Below the knee arteries are Tibio-peroneal trunk, Peroneal bifurcation, anterior tibial artery, posterior tibial artery and peroneal artery. With documented Distal Run off a maximum of two tibial vessels can be treated in the index procedure. Inflow free from flow limiting lesions (\<50% stenosis) confirmed by duplex or angiography. Subjects with flow limiting inflow lesions (\>50% stenosis) can be included if lesion had been treated successfully (\<30% residual stenosis) before or during the index procedure.

• Target vessel has angiographically documented unimpaired (\<50% stenosis) run off into a named Tibio-pedal artery (Peroneal, Anterior Tibial/ Dorsalis Pedis/ Posterior Tibial Artery)

Locations
United States
Arizona
Honor Health Research & Innovation Institute
RECRUITING
Scottsdale
California
University of California Los Angeles
NOT_YET_RECRUITING
Los Angeles
Florida
Clearwater Cardiovascular Consultants
RECRUITING
Clearwater
Baptist Hospital of Miami
RECRUITING
Miami
University of South Florida
RECRUITING
Tampa
Iowa
Vascular Institute of the Midwest
RECRUITING
Davenport
Unity Point Health Des Moines
RECRUITING
Des Moines
New Jersey
Deborah Heart and Lung Center
RECRUITING
Browns Mills
Virtua Healthcare - Virtua Our Lady of Lourdes
RECRUITING
Marlton
New York
Northwell Health Long Island Jewish Medical Center
RECRUITING
Lake Success
Columbia University Irving Medical center/NYPH
RECRUITING
New York
New York Presbyterian - Weill Cornell Medical Center Vascular & Endovascular Surgery
RECRUITING
New York
The Mount Sinai Hospital
RECRUITING
New York
Westchester Medical Center
RECRUITING
Valhalla
Ohio
The Christ Hospital Network Outpatient Center
RECRUITING
Cincinnati
University Hospitals Cleveland Medical Center
RECRUITING
Cleveland
Pennsylvania
Lankenau Institute for Medical Research Bryn Mawr Hospital
RECRUITING
Bryn Mawr
University of Pennsylvania - Penn Heart and Vascular Center
RECRUITING
Philadelphia
South Carolina
Medical University of South Carolina(MUSC) Health Ashley River Tower
RECRUITING
Charleston
Texas
Ascension Seton Medical Center Austin
RECRUITING
Austin
Baylor Research Institute
RECRUITING
Dallas
The Heart Hospital Baylor Plano
RECRUITING
Plano
Washington
University of Washington Seattle
RECRUITING
Seattle
Contact Information
Primary
Farhana Siddique
farhana@conceptmedical.com
+919725495366
Backup
Dario Gattuso
dario@conceptmedical.com
+393292467132
Time Frame
Start Date: 2025-01-16
Estimated Completion Date: 2031-02-01
Participants
Target number of participants: 368
Treatments
Active_comparator: MagicTouch PTA sirolimus DCB
MagicTouch PTA sirolimus drug coated balloon (DCB) in addition to standard balloon angioplasty
Placebo_comparator: Placebo balloon angioplasty
Placebo balloon angioplasty in addition to standard balloon angioplasty (PTA)
Sponsors
Leads: Concept Medical Inc.

This content was sourced from clinicaltrials.gov